HegedsLShermanSITuttleRMvon ScholtenBJRasmussenSKarsblJDet al
2012;97(7):E11659
Risk Assessment: Evaluate the nature and extent of PHI, the unauthorized person who used/received it, whether it was actually acquired or viewed, and the extent to which the risk has been mitigated
GLP-1 medications are extremely valuable in this population but increasingly as: Prehabilitation tools Adjunct therapy Postoperative optimization Long-term weight maintenance support What we are learning: GLP-1s are bringing more patients into obesity care Surgery remains unmatched for long-term total body weight loss and metabolic remission in severe obesity The most successful programs will integrate medications, endoscopy, and surgery into one coordinated pathway The future will be driven by: BMI stratification Metabolic disease burden Precision medicine Longitudinal follow-up Multidisciplinary care Obesity is a chronic disease
One-on-one coaching for continuous motivation
Albritton KH, Rankin C, Coffin CM, Ratner N, Budd GT, Schuetze SM, et al